Amicus Therapeutics, Inc. (NASDAQ:FOLD) is considered one of the best biotech stocks to buy by billionaire Steve Cohen. Morgan Stanley upgraded FOLD to Overweight with a $12 price target, citing strong intellectual property and financials, including a 90.6% gross margin and a current ratio of 3.34.

Morgan Stanley adjusted sales forecasts slightly below consensus for Galafold and PomOp but remains bullish due to Amicus’s recent licensing of DMX-200 for FSGS treatment. With strategic supply chain planning and U.S. inventory in place, minimal tariff impact is expected in 2025, reinforcing operational resilience.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a global biotechnology company specializing in developing transformative medicines for rare metabolic diseases. Leveraging innovative technology platforms, Amicus emphasizes patient needs in creating treatments for genetic diseases.

While FOLD has investment potential, certain AI stocks may offer greater upside. For an undervalued AI stock benefiting from Trump-era tariffs and onshoring trends, consider our free report on the best short-term AI stock.

Read more at Yahoo Finance: Morgan Stanley Upgrades Amicus (FOLD) on IP Strength and Pipeline Expansion